OP0322-HPR EMPOWERMENT AND ASSOCIATIONS TO DISEASE ACTIVITY AND PAIN IN PATIENTS WITH RHEUMATOID ARTHRITIS
Authors: M. Andersson, A. Bremander, I. Larsson
Journal: Annals of the Rheumatic Diseases (2021)

Background: The WHO describes empowerment as a process in which patients can take control and make informed decisions about their life and health. Empowerment is important for patients with rheumatoid arthritis (RA) since most of the care is provided by the patients themselves. Objectives: The aim was to study levels of empowerment and associated variables in individuals with RA and to investigate longitudinal clinical data in patients with low and high empowerment. Methods: This study involved patients with RA from the BARFOT (Better Anti-Rheumatic PharmacOTherapy) cohort, who were recruited between 1992 and 2006 and included in the study at the time for diagnosis (n = 2,837) [1]. The patients were assessed according to a structured protocol at inclusion and after 3, 6, 12, 24, 60, 96, and 180 months. At each follow-up DAS28-3, HAQ and pain were assessed. In 2017, a postal survey was sent to all still living patients (n=1542), with a response rate of 69% (n = 1,065). The questionnaire included disease characteristics, questions about lifestyle habits and the Swedish Rheumatic Disease Empowerment Scale (SWE-RES-23) [2]. The 844 patients who answered the SWE-RES-23 made up the study cohort. Differences in empowerment between groups (lowest third [LE], SWE-RES-23 ≤3.48 vs. highest third [HE], SWE-RES-23 ≥4.04) were analysed with t-tests. Logistic regression analysis was used to study associations with LE vs. all others. Thirdly, differences between LE and HE were studied with longitudinal data (seven time points) of pain, HAQ and disease activity. Results: Responders were mean 65 (SD13) years old, disease duration 15.6 (3.9) years, and 74% were women. The LE group (n=282) were older and were more often women, and reported worse overall health compared with the HE group (n=270), Table 1. Table 1. Descriptives at questionnaire 2017, including all participants and comparisons between highest and lowest third of SWE-RES-23 All Mean (sd) Low SWERES* Mean (sd) High SWERES* Mean (sd) p-value N 844 282 270 Sex, women, % 74 78 69 0.015 Age 65 (13) 66 (13) 63 (12) 0.002 Disease duration, year 15.6 (3.9) 15.7 (4.1) 15.6 (3.8) 0.917 TJC28 (0-28) 5 (6) 6 (8) 4 (5) &lt;0.001 SJC28 (0-28) 3 (5) 3 (4) 3 (4) 0.334 PatGA (0-10) 3 (2) 4 (3) 2 (2) &lt;0.001 Pain (0-10) 3 (2) 4 (3) 3 (2) &lt;0.001 Fatigue (0-10) 4 (3) 5 (3) 3 (3) &lt;0.001 HAQ (0-3) 0.62 (0.61) 0.81 (0.69) 0.42 (0.51) &lt;0.001 EQ5D (0-1) 0.70 (0.25) 0.62 (0.29) 0.79 (0.19) &lt;0.001 SWERES 3.8 (0.7) 3.1 (0.3) 4.6 (0.3) &lt;0.001 *tricotomized data, lowest third vs. highest third Regarding lifestyle habits, there were no differences between the groups in smoking habits, diets, or drinking habits. Moderate physical activity for ≥150 min/week was reported by 27% in the LE group vs. 41% in the HE group, p&lt;0.001. Vigorous physical activity ≥60 min/week was reported by 22% vs. 37% in the LE and the HE group respectively, p&lt;0.001. In the logistic regression analysis (n=844), several factors were associated with LE: being a woman (OR 1.40, 95% CI 1.00-1.97), pain-related factors as higher tender joint count (OR 1.04, 95% CI 1.01-1.06), worse patient global assessment (OR 1.19, 95% CI 1.12-1.27), pain (OR 1.14, 95% CI 1.08-1.21), fatigue (OR 1.14, 95% CI 1.09-1.21), HAQ (OR 2.08, 95% CI 1.64-2.64) and EQ-5D (OR 0.16, 95% CI 0.09-0.28). There were also associations between moderate physical activity (&lt;150 min/week) (OR 1.60, 95% CI 1.16-2.19) and vigorous (&lt; 60min/week) (OR 1.50, 95% CI 1.07-2.10) and LE. Analysing longitudinal data, the LE group reported worse pain and HAQ at all timepoints, a worse DAS28-3 at year 2 and 8, and a worse ESR at 15 years follow-up compared with the HE group (p&lt;0.05). Conclusion: In patients with RA, low empowerment is associated with worse all over health. Interventions aimed to improve empowerment may include mastering of pain, physical function, and improved physical activity. References: [1]Hafstrom I et al. Open Access Rheumatol 2019;11:207-17. [2]Arvidsson S et al. Musculoskeletal Care 2012;10:101-9. Figure 1. Panel showing mean DAS28-3 (A), ESR (B), VAS pain (C) and HAQ (D) over 15 years in the different groups. Disclosure of Interests: None declared.